Methylsulfonylmethane (MSM) for treatment of drug resistant microorganisms
Embodiments of the invention relate generally to the use of compositions comprising methylsulfonylmethane (MSM), and one or more therapeutic agents, for the treatment of drug-sensitive and drug resistant microorganisms. In several embodiments, such compositions are effective in treating drug resistant infectious diseases, for example, MRSA.
1. A method of sensitizing methicillin resistant Staphylococcus aureus (MRSA) to a Beta-lactam antibiotic to which the MRSA is resistant, the method comprising:
selecting MRSA resistant to the Beta-lactam antibiotic; and
contacting the MRSA with a composition comprising a therapeutically effective amount of methylsulfonylmethane (MSM), thereby sensitizing the MRSA to the Beta-lactam antibiotic.
2. The method of claim 1 , wherein the Beta-lactam antibiotic is selected from the group consisting of a penicillin derivative, a cephalosporin, a penem, a monobactam, a carbapenem, a Beta-lactamase inhibitor or a combination of two or more thereof.
3. The method of claim 2 , wherein the Beta-lactam antibiotic is a penicillin derivative.
4. The method of claim 3 , wherein the penicillin derivative is methicillin or oxacillin.
5. The method of claim 1 , wherein the therapeutically effective amount of MSM is about 5-16% MSM, about 5-10% MSM, about 5-8% MSM, about 9-16% MSM or about 10-15% MSM.
6. The method of claim 1 , wherein the therapeutically effective amount of MSM is about 12-13% MSM.
7. The method of claim 1 , wherein the therapeutically effective amount of MSM is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16% MSM.
8. The method of claim 1 , wherein the composition further comprises 0-5% sodium chloride.
9. The method of claim 1 , further comprising inhibiting the MRSA, comprising:
contacting the sensitized MRSA with a composition comprising a therapeutically effective amount of the Beta-lactam antibiotic, thereby inhibiting the MRSA.
10. The method of claim 9 , wherein the Beta-lactam antibiotic is selected from the group consisting of a penicillin derivative, a cephalosporin, a penem, a monobactam, a carbapenem, a Beta-lactamase inhibitor or a combination of two or more thereof.
11. The method of claim 10 , wherein the Beta-lactam antibiotic is a penicillin derivative.
12. The method of claim 11 , wherein the penicillin derivative is methicillin or oxacillin.
13. The method of claim 9 , wherein the therapeutically effective amount of MSM is about 5-16% MSM, about 5-10% MSM, about 5-8% MSM, about 9-16% MSM or about 10-15% MSM.
14. The method of claim 9 , wherein the therapeutically effective amount of MSM is about 12-13% MSM.
15. The method of claim 9 , wherein the therapeutically effective amount of MSM is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16% MSM.
16. A method of sensitizing methicillin resistant Staphylococcus aureus (MRSA) to a penicillin derivative to which the MRSA is resistant, the method comprising:
selecting MRSA resistant to the penicillin derivative; and
contacting the MRSA with a composition comprising about 12-13% methylsulfonylmethane (MSM), thereby sensitizing the MRSA to the penicillin derivative.
17. The method of claim 16 , wherein the penicillin derivative is methicillin or oxacillin.
18. A method of inhibiting methicillin resistant Staphylococcus aureus (MRSA) that is resistant to a penicillin derivative, comprising:
selecting MRSA resistant to the penicillin derivative; and
contacting the MRSA with a composition comprising about 12-13% methylsulfonylmethane (MSM) and a therapeutically effective amount of a penicillin derivative, thereby inhibiting the MRSA.
19. The method of claim 18 , wherein the penicillin derivative is methicillin or oxacillin.